Abstract
MART-1 (melanoma antigen recognized by T cells) is also known as Melan-A. It has gained wide acceptance as an immunohistochemical marker to diagnose melanoma in biopsy material. MART-1 is not expressed in tissues lacking melanin pigment. Cellular and humoral immune responses against MART-1 have been detected in patients with melanoma and substantial efforts are ongoing to develop MART-1 as a therapeutic target in conjunction with T-cell checkpoint antibodies, cellular immunotherapy and peptide vaccines using a variety of adjuvants.
Author supplied keywords
- Animal models
- Antigens
- Gene
- Human immune responses
- Immunohistochemical staining panels
- Immunotherapy
- In cancer
- Ipilimumab
- Malignant melanocytes
- Melan-A. See Melanoma antigen recognized by T cells (MART-1)
- Melanoma antigen recognized by Tcells (MART-1)
- Nonamer and decamer peptides
- OA1
- Predictive marker
- T-cell immune response
- Vaccines and cellular therapy
Cite
CITATION STYLE
Curti, B. D. (2017). MART-1. In Cancer Therapeutic Targets (Vol. 1–2, pp. 385–390). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_50
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
